CVS Health Corp.
Analysis
CVS has become a story about one business fixing itself fast enough to cover another one shrinking. Three straight quarters of raised guidance come from Aetna, the health insurer, while the pharmacy-benefit arm that brings in the most revenue loses members and profit. How much of total revenue still comes from the pharmacy-benefit arm?
- Aetna's turnaround is now the whole earnings story.
The insurer went from a loss in 2024 to a profit that management expects to nearly double this year, and it drove every guidance raise since. Full-year 2026 profit guidance is up $0.90 a share from December, and Aetna is why.
- The pharmacy-benefit business is shrinking, and management said so early.
In Q2 FY2026 management named next year's problems a quarter early: 340B, client losses, and retention below their own record. Caremark is the biggest revenue source, so a smaller book pulls the whole company's growth down. Which clients are leaving Caremark, and how much profit goes with them?
- Retail pharmacy stopped being the problem and became the steady base.
Two years of investment in service and technology, plus a completed switch to cost-based pricing, turned a business expected to shrink 5% a year into one management now says will hold at least flat. It no longer needs rescuing. How much of the pharmacy's script growth came from Rite Aid, not new demand?
- Aetna margin recoveryThe bull case rests on Aetna, where two years of repricing and disciplined bidding have turned a loss-making insurer into the fastest-improving part of the company.
- Retail pharmacy turnaroundRetail pharmacy has gone from a business expected to shrink to one that grows earnings, helped by cost-based reimbursement and share gains from failed competitors.
- Repeated guidance raisesManagement has raised its full-year earnings outlook at each of the last several reports and argues the growth it promises for next year is credible rather than aspirational.
- PBM client renewalsThe bear case says the pharmacy benefit business is losing clients and repricing contracts at lower economics, so its profit shrinks while the rest of the company improves.
- Medicare rate settingGovernment rate notices have lagged medical cost trends for years, so Aetna's recovery depends on repricing and benefit cuts that may be hard to repeat each year.
- State pharmacy lawsStates are passing laws that restrict how the pharmacy and PBM businesses contract with each other, and CVS is fighting them in court rather than pricing around them.
| Politician | Transaction | Amount | Traded | Filed |
|---|---|---|---|---|
Donald Trump Republican · Executive | Sale | ≥$100K | Jul 31 | Sep 22 |
Donald Trump Republican · Executive | Purchase | ≥$1K | May 15 | Jul 1 |
Donald Trump Republican · Executive | Purchase | ≥$1K | May 11 | Jul 1 |
Donald Trump Republican · Executive | Purchase | ≥$1K | Mar 17 | May 13 |
Ro Khanna Democratic · House · CA-17 | Sale | ≥$1K | Aug 24 | Sep 4 |
Congressional trading data provided by QuiverQuant
How CVS Health turned $402B of revenue into $4.7B of operating income.
| Revenue | ||
|---|---|---|
| Pharmacy Revenue | $229B | ▲ 8.92% YoY |
| Premiums | $135B | ▲ 9.65% YoY |
| Front Store Revenue | $21.5B | ▼ 0.29% YoY |
| Product and Service, Other | $3.9B | ▼ 75.41% YoY |
| Total revenue | $402B | |
| Operating income | $4.7B | 1.2% |